Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party

Leukemia volume 29, pages 686–688 (2015)Cite this article

Subjects

Abstract

The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Falchook GS, Vega F, Dang NH, Samaniego F, Rodriguez MA, Champlin RE et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol 2009; 20: 1080–1085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tripodo C, Iannitto E, Florena AM, Pucillo CE, Piccaluga PP, Franco V et al. Gamma-delta T-cell lymphomas. Nat Rev Clin Oncol 2009; 6: 707–717.

    Article  PubMed  Google Scholar 

  3. Belhadj K, Reyes F, Farcet JP, Tilly H, Bastard C, Angonin R et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261–4269.

    Article  CAS  PubMed  Google Scholar 

  4. Vega F, Medeiros LJ, Gaulard P . Hepatosplenic and other gammadelta T-cell lymphomas. Am J Clin Pathol 2007; 127: 869–880.

    Article  CAS  PubMed  Google Scholar 

  5. Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124–4130.

    Article  PubMed  Google Scholar 

  6. Weidmann E . Hepatosplenic T cell lymphoma: a review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991–997.

    Article  CAS  PubMed  Google Scholar 

  7. Shustov A, Wilson W, Beaven A, Savage JK, Carson RK, Hernandez-Ilizaliturri JF et al. Hepatosplenic T-cell lymphoma: clinicopathological features and treatment outcomes: report from the North American Peripheral T-Cell Lymphoma Consortium. Blood 2013; 122: abstr 3032.

  8. Le Gouill S, Milpied N, Buzyn A, Peffault De Latour R, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.

    Article  PubMed  Google Scholar 

  9. Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau JL, Kolb HJ et al. Allogeneic stem cell transplantation is able to inducelong-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009; 27: 3951–3958.

    Article  PubMed  Google Scholar 

  10. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520–526.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all EBMT centres that participated in this study.

Author Contributions

AT and PD proposed the study, interpreted the data and wrote the manuscript. NS helped in interpreting data and writing the manuscript. AB helped with the design and was responsible for statistical analysis. HS provided the expert histopathology review. HF was the study coordinator. LC, DB, NM, GS, AS, KT, EV, AV reported updated patient data and read and commented on the manuscript. Additional colleagues reporting data into the study are listed in Appendix below. All authors proofread the manuscript and agreed on the data presented.

Author information

Authors and Affiliations

  1. EBMT Lymphoma Working Party, Paris, France

    A Tanase, N Schmitz, A Boumendil, H Finel, A Sureda & P Dreger

  2. BMT Department, Fundeni Clinical Institute, Fundeni Hospital, Bucharest, Romania

    A Tanase

  3. Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany

    N Schmitz

  4. Pathodiagnostik Berlin, Berlin, Germany

    H Stein

  5. Humanitas Cancer Center, Rozzano, Italy

    L Castagna

  6. Institut Paoli Calmettes, Marseille, France

    D Blaise

  7. CHU Bordeaux, Bordeaux, France

    N Milpied

  8. Gazi Universitesi Tip Fakultesi, Ankara, Turkey

    G Sucak

  9. Servei d’ Hematologia, Institut Catala d’Oncologia- Hospital Duran i Reynals, Barcelona, Spain

    A Sureda

  10. University College London Hospital, London, UK

    K Thomson

  11. St James’s Hospital, Dublin, Ireland

    E Vandenberghe

  12. Institute of Hematology and Blood Transfusion, Prague, Czech Republic

    A Vitek

  13. Department of Medicine, University of Heidelberg, Heidelberg, Germany

    P Dreger

Authors
  1. A Tanase
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Boumendil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Finel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N Milpied
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Sucak
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. K Thomson
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. E Vandenberghe
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A Vitek
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. P Dreger
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the Lymphoma Working Party of the EBMT

Corresponding author

Correspondence to A Tanase.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Appendix

Appendix

Investigators and institutions not included in the author list

  • Irit Avivi, Rambam Medical Center, Haifa, Israël

  • Ali Bazarbachi, American University of Beirut Medical Center, Beirut, Lebanon

  • Wolfgang Bethge, Universität Tübingen, Tübingen, Germany

  • Ildefonso Espigado, Hospital Universitario Virgen del Rocío, Sevilla, Spain

  • Edgar Faber, University Hospital, Olomouc, Czech Republic

  • Nathalie Fegueux, CHU Lapeyronie, Montpellier, France

  • Bertram Glass, Asklepios Klinik St. Georg, Hamburg, Germany

  • Hannah Hunter, Plymouth Hospitals NHS Trust, Plymouth, UK

  • Norbert Ifrah, CHRU, Angers, France

  • Per Ljungman, Karolinska University Hospital, Stockholm, Sweden

  • Mauricette Michallet, Centre Hospitalier Lyon Sud, Lyon, France

  • Jose Maria Moraleda, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

  • Reuven Or, Hadassah University Hospital, Jerusalem, Israël

  • Xavier Poiré, Cliniques Universitaires St. Luc, Brussels, Belgium

  • Jose Pretnar, University Med. Center, Ljubljana, Slovenia

  • Alessandro Rambaldi, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

  • Deniz Sargýn, Istanbul Tip Fakuoltesi, Istanbul, Turkey

  • Simona Sica, Universita Cattolica S. Cuore, Rome, Italy

  • John Snowden, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK

  • Alexandros Spyridonidis, Patras University Medical School, Patras, Greece

  • Jean Paul Vernant, Hôpital de la Pitié-Salpètrière, Paris, France

  • Anders Wahlin, Umea University Hospital, Umeå, Sweden

  • Moshe Yeshurun, Beilinson Hospital, Petach-Tikva, Israël

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanase, A., Schmitz, N., Stein, H. et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia 29, 686–688 (2015). https://doi.org/10.1038/leu.2014.280

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2014.280

This article is cited by

Search

Advanced search

Quick links